How GLP-1 Users Utilize Digital Health Apps in the US: A Quantitative Research Case Study

Research type: Quantitative market research
Target sample: 75 respondents
Market: United States

Executive Summary

Digital health applications are becoming an important part of the GLP-1 treatment experience, supporting weight tracking, nutrition management, symptom monitoring, and medication reminders. To understand this behavior, quantitative research involving 75 US respondents examined app adoption, engagement, satisfaction, and willingness to pay for digital health solutions.

The findings show that 72% of respondents use at least one digital health application. Weight and progress tracking lead reported use cases at 68.5%, followed by nutrition tracking at 61.1% and symptom logging at 42.6%.

However, adoption does not automatically translate into a seamless digital experience. Respondents identified better integration and simpler tracking as improvement priorities. Meanwhile, 32% expressed willingness to pay for digital health services, indicating potential for premium offerings among users who perceive sufficient value.

For digital health companies, the findings highlight an opportunity to improve GLP-1 medication app usage through integrated, user-friendly experiences that complement treatment and support sustainable lifestyle changes.

1. Digital Health Adoption Among GLP-1 Users in the US

The survey found that 72% of respondents used at least one digital health application, while 28% did not report using such tools.

This adoption pattern suggests that digital applications can play a meaningful role in the GLP-1 treatment journey. However, the findings should be interpreted as directional because the study included only 75 respondents and may not represent the broader US GLP-1 population.

For healthcare technology companies, the non-user segment presents an opportunity to investigate barriers such as onboarding complexity, limited awareness, manual data entry, and a lack of perceived value. These are potential explanations that require further validation rather than confirmed reasons established by this survey.

Effective digital health adoption in the US depends on more than application availability. Users need tools that fit naturally into their daily routines and provide practical benefits without adding unnecessary administrative effort.

2. How GLP-1 Users Use Digital Health Apps

Understanding how GLP-1 users use digital health apps helps digital health developers identify the features most closely aligned with patient needs.

The survey identified four principal use cases:

Source: Quantitative research, target sample of 75 US respondents. Percentages are reported as supplied in the study.

Weight management and progress tracking

Weight and progress tracking was the leading reported use case, at 68.5%. This finding reinforces the importance of visible, easy-to-understand progress indicators in weight management apps for GLP-1 users.

Applications can support this need through weight histories, trend visualizations, milestone tracking, and personalized progress summaries. The objective should be to help users interpret changes over time rather than focus exclusively on individual measurements.

Nutrition tracking and lifestyle support

Nutrition tracking ranked second, with 61.1% of respondents reporting this use case. This points to interest in digital support that extends beyond medication management.

Potential features include meal logging, hydration tracking, nutrition education, and tools for monitoring dietary habits. Developers should prioritize accessible interfaces and practical guidance instead of making routine logging unnecessarily complex.

These findings suggest that digital health apps for GLP-1 users may deliver greater perceived value when they connect medication-related experiences with everyday lifestyle management.

Symptom logging and medication reminders

Symptom logging was reported by 42.6% of respondents, while medication reminders were used by 38.9%.

These use cases highlight two distinct needs: documenting treatment experiences and supporting medication routines. Symptom-tracking features could allow users to record changes and prepare more structured information for discussions with healthcare professionals.

Medication reminders may help users organize their routines, but an application should not replace prescribing instructions or professional medical advice. Symptom information should also be presented carefully, with clear guidance on when users should contact a healthcare professional.

Together, these behaviors provide useful evidence about digital tools for GLP-1 medication management and the potential role of applications in supporting communication and self-management.

3. GLP-1 Patient Engagement and App Satisfaction

The survey offers additional insight into GLP-1 patient engagement, including usage frequency, satisfaction, and perceived support.

• 35.2% of respondents were daily app users.
• 55.6% reported satisfaction with their digital health applications.
• 64.8% felt supported by the applications they used.

Daily usage suggests that a subset of respondents has incorporated digital tools into regular routines. However, the reported daily-use figure should not be interpreted as evidence of long-term adherence or improved clinical outcomes.

The satisfaction finding also leaves room for improvement. While more than half of respondents were satisfied, the remaining respondents may have had mixed experiences or been dissatisfied. The available results do not establish the precise reasons behind these responses.

Similarly, perceived support is a measure of user experience, not proof that an application improves treatment effectiveness.

For product teams, the practical implication is to assess the complete user journey: initial onboarding, routine tracking, interpretation of progress, symptom documentation, and ongoing engagement. Understanding where users encounter friction can help companies prioritize product improvements.

4. What Do GLP-1 Users Want from Digital Health Applications?

The survey identified two prominent improvement priorities: better integration, cited by 26.7% of respondents, and simpler tracking, cited by 24%.

Better integration across health activities

The demand for integration suggests an opportunity to connect weight trends, nutrition records, medication routines, and symptom histories in a more cohesive experience.

Rather than requiring users to navigate disconnected features, digital health platforms could offer unified dashboards and compatible data-sharing capabilities. Where appropriate and authorized, integrations with health records, connected devices, and other health applications may reduce duplicated data entry.

Companies developing these products should evaluate interoperability, privacy, consent management, and data accuracy before expanding integrations.

Simpler tracking and improved usability

The 24% preference for simpler tracking highlights the importance of reducing the effort required to maintain consistent records.

Potential improvements include streamlined logging, customizable reminders, clearer navigation, and progress summaries that do not require users to interpret complicated charts.

For product developers, usability should be measured through observable indicators such as task completion, time required to log information, onboarding completion, and continued feature use.

Improving these fundamentals may be more valuable than adding numerous advanced features that increase complexity without addressing established user needs.

5. Monetization Opportunities for Digital Health Companies

The survey found that 32% of respondents were willing to pay for digital health applications or services. This indicates a potential premium audience, but it does not establish how much users would pay or whether they would convert to a paid subscription.

A sustainable monetization strategy should connect pricing with a clearly differentiated user benefit.

Potential premium features include:

• Advanced weight and progress analytics.
• Integrated nutrition and symptom tracking.
• Personalized progress summaries.
• Flexible reminders and tracking workflows.
• Data export and reporting features for healthcare discussions.

A freemium model could allow users to access essential tracking features at no cost while reserving selected advanced capabilities for paying customers. However, this approach should be tested rather than assumed to be optimal.

Pricing research should evaluate subscription preferences, willingness to pay at specific price points, feature priorities, and conversion intent. Companies should also assess retention and cancellation behavior to determine whether perceived value persists after initial adoption.

The broader GLP-1 user behavior findings suggest that monetization may depend on delivering a simpler, more integrated experience rather than merely increasing the number of available features.

6. Industry Insights: What Healthcare Technology Companies Should Consider

The study points to three strategic priorities for companies developing digital health solutions around GLP-1 treatment.

First, build around the user's daily needs. Weight tracking and nutrition management were the leading reported use cases. Product roadmaps should reflect these established behaviors before prioritizing less frequently reported features.

Second, connect the treatment experience. The reported demand for integration creates an opportunity to bring relevant information together while maintaining appropriate privacy and consent safeguards.

Third, validate engagement and commercial value separately. App adoption, daily use, satisfaction, willingness to pay, and clinical outcomes are different measures. Strong performance in one does not automatically establish success in another.

Established digital health platforms, including MyFitnessPal, Noom, and Apple Health, offer relevant examples of nutrition tracking, behavior-change support, and health-data aggregation. Their presence in adjacent categories illustrates the breadth of capabilities available in the digital health ecosystem; it does not establish that they are specifically preferred by respondents in this study.

Healthcare technology companies can differentiate by designing experiences tailored to the needs of GLP-1 users, including streamlined tracking, meaningful progress summaries, and tools that help users organize information for healthcare consultations.

Future research should investigate differences by medication type, treatment duration, app category, age group, and user goals. Larger and more representative samples would also help validate whether these patterns hold across the US market.

7. Research Limitations

This study used a target sample of 75 respondents. The results should therefore be treated as directional market research rather than representative estimates for all US GLP-1 users.

The supplied findings do not establish causality between application use and medication adherence, weight loss, satisfaction with treatment, or clinical outcomes. The survey also does not provide enough information to determine the statistical significance of differences between user groups.

Future studies could expand the sample, document recruitment and respondent characteristics, clarify the denominator for each question, and test pricing preferences at specific subscription levels.

These steps would strengthen the evidence available to digital health developers, healthcare organizations, and market researchers.

Frequently Asked Questions

1. What is GLP-1 medication app usage?

GLP-1 medication app usage refers to how people taking GLP-1 medications use digital applications to track progress, monitor nutrition, record symptoms, organize medication routines, and manage related health activities.

2. How many GLP-1 users in this study used digital health apps?

In this study of 75 US respondents, 72% reported using at least one digital health application, while 28% did not report app use. These are study-specific findings, not national prevalence estimates.

3. What are the most common digital health app features among GLP-1 users?

Weight and progress tracking was the leading reported use case at 68.5%, followed by nutrition tracking at 61.1%, symptom logging at 42.6%, and medication reminders at 38.9%.

4. How do patients track GLP-1 treatment progress?

Patients may use digital applications to record weight changes, monitor nutrition, log symptoms, and organize medication reminders. The usefulness of these features depends on usability, data quality, and how well the information supports individual needs.

5. What improvements do GLP-1 users want from health apps?

In this survey, 26.7% identified better integration as an improvement priority, while 24% wanted simpler tracking. These findings point to opportunities to reduce fragmented workflows and manual effort.

6. Are GLP-1 users willing to pay for digital health apps?

Thirty-two percent of respondents indicated willingness to pay. Actual purchasing behavior and acceptable price points were not established, so additional pricing research is needed.

7. What can healthcare technology companies learn from GLP-1 user behavior?

Companies can prioritize core tracking features, improve usability, connect relevant health information, and evaluate satisfaction alongside sustained engagement and commercial conversion.

Conclusion

The findings provide a directional view of GLP-1 medication app usage and its role in the US digital health landscape. Among the 75 respondents, application adoption was relatively high, with weight tracking, nutrition management, and symptom logging emerging as prominent use cases.

The strongest product opportunities lie in making these experiences easier to use and better integrated. Meanwhile, the reported willingness to pay suggests that selected premium features may have commercial potential, provided their value is demonstrated and pricing is validated.

For digital health companies, the next step is to move beyond adoption metrics and investigate what drives sustained engagement, user satisfaction, and meaningful support throughout the treatment journey. Larger, more representative studies will be essential to validate these findings and guide investment decisions.